United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference
The presentation and the immediately following Q&A session will take place on
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
James Edgemond at (301) 608-9292, Email: firstname.lastname@example.org